Semaglutide SM20 20mg*10vials

Smegglutide SM20 (20mg x 10 vials) is a high-purity, long-acting lyophilized GLP-1 receptor agonist developed specifically for advanced preclinical metabolic laboratory research. As an upgrade to the SM10 and SM15 series, SM20 features second-generation molecular structure optimization, resulting in higher target binding activity, stronger antioxidant and anti-degradation properties, and longer in vivo metabolic persistence. Its ultra-high 20mg concentration per vial fully meets the experimental requirements for high-dose gradient screening, long-term continuous metabolic modeling, large-scale batch sample validation, and high-standard data repeatability testing, making it a high-quality core research raw material for in-depth research on GLP-1 mechanisms and high-dose efficacy.

Product Function and Research Value

Smegglutide SM20, based on its optimized GLP-1 single-target activation characteristics, can stably mimic the physiological effects of human incretin. In professional laboratory research, SM20 is mainly used to explore its core mechanisms, including high-dose improvement of insulin resistance, long-term regulation of glycemic homeostasis, and remodeling of glucose and lipid metabolism pathways. It effectively activates appetite-suppressing signals, significantly prolongs the satiety cycle, reduces excessive energy intake, and deeply intervenes in systemic lipid metabolism and fat accumulation. Compared with the low- and medium-dose versions of SM10 and SM15, SM20 exhibits stronger biological activity, more durable experimental effects, and more significant high-dose phenotypic differences, providing more authoritative and stable data support for in-depth research on severe metabolic disorders, chronic endocrine diseases, and the mechanisms related to high-dose efficacy.

Core Product Advantages

1. SM20 Advanced Upgrade: Second-generation optimized molecular structure effectively enhances target binding activity and molecular stability. Compared with ordinary semaglutide, SM10, and SM15, SM20 has stronger anti-degradation capabilities and a longer effective duration, ensuring more stable and discriminative high-dose experimental results.

2. 20mg High-Purity Ultra-High Concentration: The concentration is twice that of the conventional 10mg specification and 1.3 times that of the 15mg specification. Perfectly suited for high-dose gradient control experiments, long-term repetitive animal model construction, and large-scale parallel sample testing, significantly reducing experimental errors caused by frequent dilution and solution changes. 3. Advanced vacuum lyophilization process: Employing aseptic, high-purity lyophilization technology to fully lock in the peptide's biological activity. Each batch undergoes rigorous HPLC purity testing and comes with complete COA quality certification, exhibiting extremely low impurity content and excellent batch consistency. 4. Standard 10-bottle/box bulk packaging: Each box contains 10 bottles in integrated aseptic packaging, perfectly suitable for long-term laboratory storage, high-end drug preclinical research, key university research projects, and global bulk wholesale procurement.

Smegglutide (SM20) 20mg*10 bottles is a high-purity, long-acting lyophilized GLP-1 receptor agonist, specifically designed for advanced preclinical metabolic studies. As an upgraded version of the SM10 and SM15 series, SM20 employs a second-generation molecular structure optimization process, resulting in higher target binding activity, stronger molecular antioxidant and anti-degradation properties, and a longer duration of in vivo metabolic efficacy. With a concentration of up to 20mg per vial, it is perfectly suited for high-dose gradient screening, long-term continuous metabolic modeling, large-scale batch sample validation, and high-standard data reproducibility experiments. It is a high-end core research raw material for in-depth exploration of the GLP-1 mechanism of action and conducting high-dose efficacy studies.

Core Uses and Research Value of Peptide Drugs

SM20, relying on its optimized and upgraded GLP-1 single-target activation characteristics, can stably mimic the physiological effects of incretin in vivo. In a professional research environment, it is mainly used to explore the mechanisms of improving insulin resistance at high doses, the principles of long-term glycemic homeostasis regulation, and the remodeling of glucose and lipid metabolic pathways. It can effectively activate appetite suppression signals, significantly prolong satiety, reduce energy intake, and deeply intervene in systemic lipid metabolism and fat accumulation. Compared with the low-dose and medium-dose versions of SM1, SM20 has more significant advantages.